| |
MESSAGE _ENGLISH VERSION_
|
|
| |
Appointment of Supervisory Board Members of Ryvu Therapeutics S.A. for a
new term of office
The Management Board of Ryvu Therapeutics S.A. with its registered
office in Krakow, Poland _"Company", "Issuer"_ hereby informs that the
Ordinary General Meeting of the Company appointed, effective June 25th,
2026, the Supervisory Board Members of the Company for a new term of
office, in the following composition:
1. Mr. Piotr Romanowski - Member of the Supervisory Board of the Company;
2. Mr. Tadeusz Wesołowski - Member of the Supervisory Board of the
Company;
3. Mr. Rafał Chwast - Member of the Supervisory Board of the Company;
4. Mr. Scott Z. Fields - Member of the Supervisory Board of the Company;
5. Mr. Peter Smith - Member of the Supervisory Board of the Company.
Information on the appointed Supervisory Board Members:
Mr. Piotr Romanowski
He has many years of experience in investment advisory in biotechnology,
advanced technologies and financial services. He serves as Chairman of
the Supervisory Board of Ryvu Therapeutics S.A. Dr. Romanowski has over
20 years of experience in strategic management consulting, gained as
Partner at McKinsey _ Company and PwC, where he specialized in mergers
and acquisitions strategy in financial services, oil and gas, the
pharmaceutical sector and healthcare. Mr. Piotr Romanowski was also a
member of the Management Board of Bank Millennium S.A., responsible for
Corporate and Investment Banking. He holds a PhD in molecular biology
from the University of Cambridge and a PhD in medical sciences,
specializing in cancer genetics, from the Medical University of Gdańsk.
Mr. Piotr Romanowski, according to the statement submitted to the
Company, is not entered in the Register of Insolvent Debtors maintained
pursuant to the Act on the National Court Register and does not conduct
any activities competitive to Ryvu Therapeutics S.A., does not
participate in a company competitive to Ryvu Therapeutics S.A. as a
partner in a civil-law partnership, partnership or capital company, and
does not participate in any other legal person competitive to Ryvu
Therapeutics S.A. as a member of its governing body.
Mr. Tadeusz Wesołowski
He obtained a PhD in technical sciences from the Warsaw University of
Technology. After graduation, he continued his academic work at the
university as an assistant professor. In 1990, he established and
managed PROSPER, which forms part of the NEUCA S.A. capital group. He
has repeatedly advised on and participated in creating new ventures in
the pharmaceutical market.
Mr. Tadeusz Wesołowski, according to the statement submitted to the
Company, is not entered in the Register of Insolvent Debtors maintained
pursuant to the Act on the National Court Register and does not conduct
any activities competitive to Ryvu Therapeutics S.A., does not
participate in a company competitive to Ryvu Therapeutics S.A. as a
partner in a civil-law partnership, partnership or capital company, and
does not participate in any other legal person competitive to Ryvu
Therapeutics S.A. as a member of its governing body.
Mr. Rafał Chwast
He is a graduate of the Krakow University of Economics in accounting and
AGH University of Science and Technology in Krakow in computer science.
From 1997 to 2007, he served as Vice-President of the Management Board
and Chief Financial Officer of Comarch. He was responsible for financial
supervision over the group companies, raising capital through the stock
exchange for Comarch and Interia.pl, and the acquisition of CDN. From
2003 to 2006, he also served as President of the Polish Association of
Listed Companies and was a member of the Capital Market Council
operating under the Prime Minister.
Mr. Rafał Chwast, according to the statement submitted to the Company,
is not entered in the Register of Insolvent Debtors maintained pursuant
to the Act on the National Court Register and does not conduct any
activities competitive to Ryvu Therapeutics S.A., does not participate
in a company competitive to Ryvu Therapeutics S.A. as a partner in a
civil-law partnership, partnership or capital company, and does not
participate in any other legal person competitive to Ryvu Therapeutics
S.A. as a member of its governing body.
Mr. Scott Z. Fields
Scott Z. Fields, M.D., is a medical oncologist/hematologist with more
than 30 years of experience in clinical drug development. Dr. Fields
currently serves as Chief Medical Officer at NeoTX Therapeutics.
Prior to joining NeoTX, Dr. Fields was the Global Head of Development
for Oncology at Bayer Pharmaceuticals. In this role, he was responsible
for early and late-stage development, including several novel oncology
medicines across the platforms for targeted therapies/precision
medicine, antibody-drug/alpha radiation conjugates and novel
Immuno-Oncology agents, such as Darolutamide _Androgen Receptor
inhibitor for prostate cancer_, Larotrectinb _NTRK inhibitor - tissue
agnostic_, Xofigo _Radium223 - alpha particle emitter for prostate
cancer_, Copanlisib _PI3K inhibitor for lymphoma_ and Regorafinib
_multi-kinase inhibitor for liver, colon and GIST_. Prior to his
position at Bayer, Dr. Fields held senior positions at Vertex
Pharmaceuticals, SmithKline Beecham, Amgen, Eisai, and Arno Therapeutics
and helped bring over a dozen drugs to market. He also practiced
oncology/hematology and transplant medicine in academic settings.
Dr. Fields received his medical degree from SUNY Downstate Medical
Center in New York, followed by training in internal medicine and
hematology, and oncology at Columbia University Medical Center.
Mr. Scott Z. Fields, according to the statement submitted to the
Company, is not entered in the Register of Insolvent Debtors maintained
pursuant to the Act on the National Court Register and does not conduct
any activities competitive to Ryvu Therapeutics S.A., does not
participate in a company competitive to Ryvu Therapeutics S.A. as a
partner in a civil-law partnership, partnership or capital company, and
does not participate in any other legal person competitive to Ryvu
Therapeutics S.A. as a member of its governing body.
Mr. Peter Smith
Peter Smith, Ph.D., is a pharmaceutical executive with over 20 years of
experience in drug discovery and development. He has proven experience
in company building and the discovery and development of new
therapeutics for various diseases of unmet need. Dr. Smith is Co-Founder
and currently Chief Executive Officer of Remix Therapeutics. He also
serves as Entrepreneur-In-Residence at Atlas Venture, where he is
Co-founder and Acting CSO of Amplify Medicine, as well as an advisor to
other Atlas portfolio companies.
Previously, he served as CSO at H3 Biomedicine, where his team
introduced three molecules into the clinic with precision medicine
approaches to treat various cancers. Prior to H3 Biomedicine, he was at
Millenium/Takeda, where he focused on oncology drug discovery and early
clinical development.
Dr. Smith received his PhD from Newcastle University and completed
post-doctoral training at Dana Farber Cancer Institute.
Disclaimer: This English language translation has been prepared solely
for the convenience of English speaking readers. Despite all the efforts
devoted to this translation, certain discrepancies, omissions or
approximations may exist. In case of any differences between the Polish
and the English versions, the Polish version shall prevail. Ryvu
Therapeutics S.A., its representatives and employees decline all
responsibility in this regard.
|
|
|
RB: Powołanie Członków Rady Nadzorczej Ryvu Therapeutics S.A. na nową kadencję / Appointment
of Supervisory Board Members of Ryvu Therapeutics S.A. for a new term of office
